Intalight Announces CE Certification of DREAM OCT, Marking a Key Milestone in Global Expansion

Recently, Intalight’s overseas market delivered major news: its core product, the DREAM OCT (Full-Eye OCT), has obtained EU CE certification, marking a new milestone in its global expansion journey. Dr. Li Bing, Co-founder and CEO of Intalight, commented, “Obtaining CE certification represents a critical step in Intalight’s overseas expansion. We are honored to see the DREAM OCT receive high recognition and widespread trust from ophthalmology experts worldwide, thanks to its world-leading product capabilities.”

In recent years, Ruyi Full-Eye OCT has continued to lead the domestic high-end ophthalmic equipment market,——Cumulative installed base exceeds 500 units; OCT sales revenue ranked first in China’s market share for two consecutive years, with OCT maintaining the leading market share in Q1 2025.The top ten ophthalmic hospitals in China all use this device for clinical research.

In overseas markets, Saiwei has established in-depth collaborations with more than 30 top-tier ophthalmic institutions worldwide, including the Bascom Palmer Eye Institute at the University of Miami, the Doheny Eye Institute at the University of California, Moorfields Eye Hospital in the UK, the London Retina Clinic, and the Medical University of Vienna. Its products are highly trusted by many globally influential ophthalmic experts today, including Professor Philip Rosenfeld, Professor Richard Spaide, Professor SriniVas Sadda, Professor Paulo Stanga, and other pioneers in clinical innovation. In the field of OCT technology, Saiwei also works closely with numerous OCT pioneers, particularly Professor David Huang and Professor Ricky Wang, whose groundbreaking achievements have driven the development of modern OCT and OCTA technologies.

To date, the Ruyi Full-Eye OCT has supported global ophthalmology experts in publishing over 170 high-impact SCI research papers, including the world’s first definitions and nomenclature for three diseases and three cover features in prestigious international journals, continuously expanding the cognitive boundaries of ophthalmic diagnosis and treatment. Joe Garibaldi, Chief Commercial Officer at Saiwei, stated that following CE certification, Saiwei will continue to advance the application of this disruptive technology and expand clinical collaborations with more leading global institutions and authoritative ophthalmology experts.

Ruyi Whole-Eye OCT boasts the world’s widest fundus imaging capability, featuring single-scan 150° ultra-widefield OCTA imaging that can be automatically montaged to achieve a 250° field of view—far exceeding the limitations of traditional OCT. Equipped with a panoramic anterior segment module, it covers key structures such as the cornea and anterior chamber angle, enabling integrated examination and joint analysis of both anterior and posterior segments. Furthermore, Ruyi Whole-Eye OCT pioneers a multi-lens optical design with dedicated lenses for specific purposes, allowing flexible matching to diverse application scenarios. Whether for ultra-widefield fundus imaging, detailed visualization of the macula and optic disc, quantitative anterior segment analysis, or animal research, the most appropriate lens can be selected to avoid the imaging compromises associated with “one-size-fits-all” lenses. This ensures clear and precise results in every examination, providing physicians with ease of use and confidence across all clinical settings.

By integrating proprietary optical systems with intelligent algorithms, Ruyi Whole-Eye OCT achieves comprehensive enhancements in scanning performance, image precision, and research capabilities. It delivers a faster, more accurate, and deeper imaging experience for physicians, covering multiple clinical applications including medical and surgical retina, glaucoma, cataract, refractive surgery, and cornea, thereby facilitating efficient decision-making across various subspecialties.

“Ophthalmologists have long needed an OCT solution that delivers speed, depth, and whole-eye precision without compromise. The Ruyi Whole-Eye OCT is precisely such a DREAM (Delightful, Reliable, Efficient, Advanced, and Multifaceted) OCT product,” said Dr. Peng Xianzhao, Founder, Chairman, and CTO of Saiwei.

Behind the exceptional swept-source OCT products stands a world-class, cross-border, and interdisciplinary R&D team led by Saiwei’s elite group of returnees from Silicon Valley. This team comprises Silicon Valley semiconductor engineers, top science scholars, and PhD holders with overseas experience. In addition to its existing OCT systems and biometers, Saiwei is strategically expanding its comprehensive ophthalmic product portfolio to include ultra-widefield true-color fundus cameras, femtosecond laser surgery systems (SMILE), high-end surgical microscopes, and intelligent data platforms. This strategy enables a transition from diagnosis to treatment, and from breakthroughs in key individual products to full-chain innovation across ophthalmology. Saiwei is committed to becoming a global, high-end platform company in ophthalmology, building an intelligent diagnostic and therapeutic ecosystem that covers the entire lifecycle of eye health. Currently, the femtosecond laser surgery system has completed optical system design—comparable in complexity to that of photolithography machines—and finished the manufacturing of engineering prototypes.

In the future, Saiwei will collaborate with global ophthalmology experts to focus on AI-empowered modern optical technologies, improve clinical diagnosis and treatment methods, continuously push the boundaries of optics and algorithms, provide advanced ophthalmic diagnostic and therapeutic solutions for patients and doctors worldwide, and bring more light and hope!